Bloomberg Law
Drug, Device Manufacturers to Face Hill Scrutiny in 2019
January 8, 2019
Combating high drug and device prices is a bipartisan goal in Congress, and House Democrats in control of key oversight committees have made clear their plans to pursue investigations putting pharma CEOs under scrutiny. Manufacturers need to prep now to explain policies and prepare for public relations issues.
Capabilities
Suggested News & Insights
Sidley Healthcare Investment Conference 2026Tuesday, September 22, 2026Challenging Executive Order on DEI, States Say It Gets FCA Materiality WrongJune 15, 2026Medtech Advisory Opinion Highlights Scrutiny of Physician Product Line Royalty ArrangementsJune 9, 2026Sidley Highly Ranked in Chambers USA 2026June 4, 2026DOJ’s Civil Rights Fraud Initiative Raises False Claims Act Risks for Healthcare and Life Sciences CompaniesJune 4, 2026Corporate Practice of Medicine Update: California Attorney General Examines the Friendly Professional Corporation ModelJune 3, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory